Added to YB: 2025-08-13
Pitch date: 2025-08-08
NOVO-B.CO [neutral]
Novo Nordisk A/S
-6.04%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 327.17
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 8/8/2025 - NOVOB – In-line results
NOVO-B.CO (earnings update): H1 sales +16% to DKK154.9bn, op profit +25% to DKK72.2bn. FY outlook downgraded to 8-14% CER sales growth (vs 16% H1) due to compounded GLP-1s, slower market growth, competition. Obesity sales +56%. Long-term structural growth potential remains, compounding enforcement could boost near-term. Attractive at 11.4x fwd earnings.
Read full article (1 min)